Context Therapeutics
3001 Market Street
Suite 140
Philadelphia
Pennsylvania
19104
United States
Tel: 484-451-8601
Website: http://www.contexttherapeutics.com/
Email: info@contexttherapeutics.com
About Context Therapeutics
Context is advancing a novel path to treating diseases by targeting Sigma1, a key regulator of mechanisms and pathways that drive cellular protein homeostasis and immune system regulation.YEAR FOUNDED:
2016
LEADERSHIP:
Co-Founder & CEO: Martin Lehr
Co-Founder & CSO: Felix Kim, PhD
CMO: Erard Gilles, MD, MSc
SCIENCE:
Please click here for Context's science.
40 articles with Context Therapeutics
-
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results
5/11/2022
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments.
-
Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
5/5/2022
Context Therapeutics Inc. today announced that an abstract on the results of the monotherapy portion of its ongoing Phase 2 trial of lead candidate onapristone extended release (ONA-XR) in granulosa cell tumors of the ovary was accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, at the McCormick Place Convention Center in Chicago, IL.
-
Context Therapeutics' lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
-
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
4/11/2022
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), today announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program.
-
Context Therapeutics® to Participate in Two April 2022 Investor Conferences
4/6/2022
Context Therapeutics Inc., a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2022.
-
Context Therapeutics® Reports Full Year 2021 Operating and Financial Results
3/23/2022
Context Therapeutics Inc. today announced financial results for the year ended December 31, 2021, and highlighted recent corporate accomplishments.
-
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
3/8/2022
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.
-
Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum
2/22/2022
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will deliver a corporate presentation during the Sachs 15th Annual European Life Sciences CEO Forum taking place virtually March 1-2, 2022.
-
Movers & Shakers, Jan. 7
1/7/2022
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers. -
Context Therapeutics® Strengthens Research & Development Team
1/5/2022
Context Therapeutics Inc., a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D.
-
Context Therapeutics® to Participate in Two January 2022 Investor Conferences
1/4/2022
Context Therapeutics Inc., a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022.
-
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
12/9/2021
Context Therapeutics Inc. (Nasdaq: CNTX), today announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation.
-
Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement - Dec 06, 2021
12/6/2021
Context Therapeutics Inc. announced that it has closed its previously announced private placement for the sale of 5,000,000 shares of common stock of Context Therapeutics together with warrants to purchase 5,000,000 shares of common stock, which resulted in gross proceeds to Context Therapeutics of approximately $31.25 million, before deducting offering expenses.
-
Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results
12/2/2021
Context Therapeutics Inc. (Nasdaq: CNTX), today announced financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments.
-
Context Therapeutics Inc. Announces $31.25 Million Private Placement
12/1/2021
Context Therapeutics Inc. announced that it has entered into definitive securities purchase agreements for a private placement with accredited investors of 5,000,000 shares of common stock of Context Therapeutics together with warrants to purchase 5,000,000 shares of common stock, which will result in gross proceeds to Context Therapeutics of approximately $31.25 million, before deducting placement offering expenses.
-
Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium
11/19/2021
Context Therapeutics Inc., a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, announced clinical data on onapristone extended release will be presented at the 2021 San Antonio Breast Cancer Symposium taking place virtually and in San Antonio, Texas, from December 7-10, 2021.
-
BioSpace Movers & Shakers, Nov. 5
11/5/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer
11/1/2021
Context Therapeutics Inc., a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, announced the appointment of Jennifer Minai-Azary as Chief Financial Officer and the prior appointment, in April 2021, of Alex Levit as Chief Legal Officer.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer
10/27/2021
Context Therapeutics Inc. and Wisconsin Oncology Network (WON), today announced the first patient has been dosed in the Phase 2 Trial